Pharmacokinetic profile of oral transmucosal delivery of TH104 was comparable to intravenous delivery of reference drug
Positive safety/tolerability achieved with TH104 reporting a mild side-effect profile
Planning for Phase 2 trial for moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) is ongoing and on track to initiate in 2024
Read MoremRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older
Read More